ClinicalTrials.gg
TerminatedNCT00282971Updated Apr 2, 2019Results posted

A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Inhaled Insulin (Exubera) and Standard of Care in Diabetes Mellitus Type 2, sponsored by Pfizer. Terminated at 64 sites in 7 countries. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-04-02.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated as marketing of this product will be discontinued

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
9th of 54
354 · median 60
Started
2006
with 2 others
Phase 3
7 of 54
none open now
Registered
7th of 54
by date
Lead sponsor
3 of 54
Pfizer

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 3 that started in 2006, is one of 7 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 35 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Type 2 diabetes melllitus
04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes mellitus type 2
  • Failing two or more oral anti-diabetic agents

Exclusion criteria

Exclusion Criteria:

  • Asthma,
  • Smoking
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Inhaled Insulin

    Inhaled insulin plus oral therapy

    Drug: Inhaled Insulin (Exubera)

  • Other
    Standard of Care

    Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators

    Other: Standard of Care

Interventions

  • Addition of inhaled insulin to pre-existing oral diabetes therapy.

  • OtherStandard of Care

    Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

    \[(week 24 value - baseline value)/baseline value\]\*100%

    Time frame: 4, 12 and 24 weeks

Secondary outcomes

  1. Percentage of Participants Achieving Glycemic Control by Visit

    2 definitions of good glycemic control were used: an HbA1c result of ≤6.5% or ≤7.0%

    Time frame: 4, 12 and 24 weeks

  2. Change From Baseline in FEV1 at Week 24 LOCF

    Time frame: 24 weeks

07

Results

Posted Aug 26, 2009
Limitations and caveats
Study terminated prematurely since the sponsor stopped marketing and manufacturing of EXUBERA and withdrew Market Authorization in Europe in September 2008. No efficacy, safety, or quality reason was associated with the premature halt of this study.

Participant flow

Participant flow — Overall Study
MilestoneInhaled InsulinStandard of Care
Started180171
Completed146149
Not completed3422

Outcome measures

PrimaryPercentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

\[(week 24 value - baseline value)/baseline value\]\*100%

Time frame:
4, 12 and 24 weeks
Reported as:
Mean · percentage change
Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
percentage changeInhaled InsulinStandard of Care
week 4 (n=164 and 158, respectively)-1.08 ± 0.61-0.62 ± 0.55
week 12 (n=159 and 150, respectively)-2.03 ± 0.97-1.37 ± 0.92
week 24 (n=142 and 150, respectively)-2.02 ± 1.10-1.44 ± 1.10
week 24 (LOCF, n=175 and 170, respectively)-1.94 ± 1.09-1.42 ± 1.09
SecondaryPercentage of Participants Achieving Glycemic Control by Visit

2 definitions of good glycemic control were used: an HbA1c result of ≤6.5% or ≤7.0%

Time frame:
4, 12 and 24 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Glycemic Control by Visit
Percentage of participantsInhaled InsulinStandard of Care
HbA1c<=7% at week 4 (n=165 and 158 respectively)6.10.0
HbA1c<=7% at week 12 (n=160 and 150 respectively)38.111.3
HbA1c<=7% at week 24 (n=143 and 150 respectively)34.312.0
HbA1c<=7% at wk-24 LOCF (n=178 & 170 respectively)32.012.9
HbA1c<=6.5% at week 4 (n=165 and 158 respectively)0.60.0
HbA1c<=6.5% at week 12 (n=160 &150 respectively)15.64.7
HbA1c<=6.5% at week 24 (n=143 &150 respectively)18.26.0
HbA1c<=6.5% at wk-24 LOCF(n=178 &170 respectively)15.25.9
SecondaryChange From Baseline in FEV1 at Week 24 LOCF
Time frame:
24 weeks
Reported as:
Mean · Liter
Change From Baseline in FEV1 at Week 24 LOCF
LiterInhaled InsulinStandard of Care
Change From Baseline in FEV1 at Week 24 LOCF-0.27 ± 9.85-0.08 ± 0.61

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Insulin—8/180 (4.4%)123/180 (68.3%)
Standard of Care—6/171 (3.5%)98/171 (57.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventInhaled InsulinStandard of Care
Coronary artery diseaseCardiac disorders0/1801/171
Myocardial infarctionCardiac disorders0/1801/171
Pancreatitis acuteGastrointestinal disorders0/1801/171
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/1801/171
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1801/171
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1801/171
Transient ischaemic attackNervous system disorders0/1801/171
Acute myocardial infarctionCardiac disorders1/1800/171
Cardiac failureCardiac disorders1/1800/171
Oedema peripheralGeneral disorders1/1800/171
Most frequent other events
Showing 10 of 16
Most frequent other events
EventInhaled InsulinStandard of Care
HypoglycaemiaMetabolism and nutrition disorders118/18098/171
CoughRespiratory, thoracic and mediastinal disorders10/1802/171
NasopharyngitisInfections and infestations8/1804/171
TremorNervous system disorders8/1805/171
InfluenzaInfections and infestations6/1807/171
Urinary tract infectionInfections and infestations7/1806/171
AstheniaGeneral disorders5/1806/171
HeadacheNervous system disorders2/1806/171
DizzinessNervous system disorders6/1803/171
Upper respiratory tract infectionInfections and infestations5/1805/171

Baseline characteristics

Age, Customized
Age, Customized(participants)Inhaled InsulinStandard of CareTotal
<18 years000
Between 18 and 44 years12618
Between 45 and 64 years112113225
>=65 years5652108
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled InsulinStandard of CareTotal
Female7680156
Male10491195
08

Study locations

64 sites
  • Gain Medical Center
    Coquitlam, British Columbia V3K 3P4, Canada
  • Misericordia Health Centre
    Winnipeg, Manitoba R3C 1A2, Canada
  • Maritime Research Center
    Bathurst, New Brunswick E2A 4X7, Canada
  • Office of Dr. Salim Sunderji
    London, Ontario N6P 1A9, Canada
  • Orillia Soldier's Memorial Hospital
    Orillia, Ontario L3V 2Z6, Canada
  • Douglas Tweel M.D. Professional Corporation
    Charlottetown, Prince Edward Island C1A 1L2, Canada
  • Laboratoire Sante Le Gaspesien Inc.
    Bonaventure, Quebec G0C 1E0, Canada
  • Centre de santé et de services sociaux de Chicoutimi, Centre de médecine genique communataire
    Chicoutimi, Quebec G7H 5H6, Canada
  • Rhodin Recherche Clinique
    Drummondville, Quebec J2B 1H8, Canada
  • Q & T Research Outaouais Inc.
    Gatineau, Quebec J8Y 6S9, Canada
  • Hopital Charles LeMoyne
    Greenfield Park, Quebec J4V2H1, Canada
  • Hopital Laval
    Saint-Foy, Quebec G1V 4G5, Canada
  • Centre Medical des Carrieres
    St-Marc-des-Carrieres, Quebec G0A 4B0, Canada
  • CIC Mauricie Inc.
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Hotel Dieu CHU, Clinique d´Endocrinologie, Maladie Metaboliques, Nutrition
    Nantes, Cedex 01 F-44035, France
  • Groupe Hospitalier Sud/Service d'Endocrinologie
    Amiens cedex 1, 80094, France
  • Private Practise
    Armentieres, 59427, France
  • Service d'Endocrinologie-
    Bondy Cedex, 93143, France
  • Hopital LA Cavale Blanche, Service de Diabetologie
    Brest CEDEX, 29609, France
  • CHU Cote de Nacre, Service d'Endocrinologie
    Cean Cedex, 14033, France
  • Private Practise
    Chartres, 28000, France
  • Office of Antoine Lemaire, MD
    Lille, 59000, France
  • Centre Hospitalier Bretagne Sud
    Lorient Cedex, 56322, France
  • Hopital Lapeyronnie Sce des Maladies
    Montpellier CEDEX 5, 34295, France
  • Hopital Bichat, Service d'Endocrinology
    Paris Cedex 18, 75877, France
  • Hopital Saint Michel
    Paris, 75015, France
  • Hopital Robert Debre
    Reims, 51100, France
  • C.H. Sud, Diabetologie
    Rennes, 35056, France
  • Centre Hospitalier Victor Provo
    Roubaix, 59100, France
  • Hôpital Jeanne d'Arc - Dommartin les Toul
    Toul Cedex, 54201, France
  • General Hospital of Athens "Laikon", 1st Propedeutic University Internal Medicine Clinic
    Athens, 11527, Greece
  • "Hygeia" Diagnostic and Therapeutic Center of Athens, Diabetes Clinic
    Athens, 151 23, Greece
  • "ATTIKON" University General Hospital, 2nd Propedeutic University Internal Medicine Clinic
    Haidari, 124 62, Greece
  • Peripheral General Hospital of Nikaia "Ag. Panteleimon", Internal Medicine Department
    Pireaus, 18454, Greece
  • University General Hospital of Thessaloniki "A.H.E.P.A." 1st Propedeutic University Internal Medicin
    Thessaloniki, 546 36, Greece
  • Hospital Infante D. Pedro
    Aveiro, 3814-096, Portugal
  • Hospitais da Universidade de Coimbra
    Coimbra, 3000-075, Portugal
  • Associação Protectora dos Diabéticos de Portugal
    Lisboa, 1250-203, Portugal
  • Serviço de Endocrinologia - Hospital de Egas Moniz
    Lisboa, 1300, Portugal
  • Hospital Geral de Santo António
    Porto, 4099-001, Portugal
  • Centro Hospitalar de Torres Vedras
    Torres Vedras, 2560-324, Portugal
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
  • Hospital de Conxo
    Santiago de Compostela, A Coruña 15706, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, Asturias 33006, Spain
  • Hospital de Bellvitge
    Hospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Mutua de Terrassa
    Terrassa, Barcelona 08221, Spain
  • Clinica Universitaria de Navarra
    Pamplona, Navarra 31008, Spain
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital General Universitario Valle de Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Puerta de Hierro
    Madrid, 28035, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital de Mostoles
    Madrid, 28935, Spain
  • Complejo Hospitalario Carlos Haya Hospital Civil - Pabellon C
    Malaga, 29009, Spain
  • Hospital Montecelo
    Pontevedra, 36071, Spain
  • Hospital Universitario La Fe
    Valencia, 46009, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • Hospital Clinico Universitario Lozano Blesa
    Zaragoza, 50009, Spain
  • Sodersjukhuset
    Stockholm, 118 83, Sweden
  • Karolinska US Huddinge
    Stockholm, 141 86, Sweden
  • Ängelholms sjukhus
    Ängelholm, 262 81, Sweden
  • Hacettepe University Medical School Department of Endocrinology
    Anakara, Turkey
  • Istanbul University Istanbul Medical School, Department of Endocrinology
    Istanbul, 34390, Turkey
  • Dokuz Eylul University Medical School, Department of Endocrinology
    Izmir, 35340, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2006 to primary completion in Feb 2008, 23 months.

Results were first posted in Aug 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2006
First posted
Jan 27, 2006
StartActual
Mar 6, 2006
Primary completionActual
Feb 19, 2008
CompletionActual
Feb 19, 2008
Results first posted
Aug 26, 2009
Last update
Apr 2, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00282971
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 27, 2006
Start date
Mar 6, 2006
Primary completion
Feb 19, 2008
Completion
Feb 19, 2008
Results posted
Aug 26, 2009
Last update
Apr 2, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion